Citation Impact
Citing Papers
PI3Kδ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic
2011
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
2016
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
2017 Standout
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Targeting Wnt pathway in mantle cell lymphoma-initiating cells
2015
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
2021
CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells
2018
The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
2013
A view on drug resistance in cancer
2019 StandoutNature
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells
2017 Nature
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ
2015
Synergy in activating class I PI3Ks
2015
OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML
2013
Macrophages in immunoregulation and therapeutics
2023 Standout
A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy
2016
Kinase inhibition in autoimmunity and inflammation
2020
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
2015
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
2018
Delivery technologies for cancer immunotherapy
2019 Standout
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer
2014
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Apoptosis in cancer: from pathogenesis to treatment
2011 Standout
Inhibiting eukaryotic transcription. Which compound to choose? How to evaluate its activity?
2011 Standout
The generation, activation, and polarization of monocyte-derived macrophages in human malignancies
2023
Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
2013
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
2011
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms
2019
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
2016
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
2013
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
2015
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Mitochondria as multifaceted regulators of cell death
2019 Standout
Macrophage M1/M2 polarization
2020 Standout
The PI3K Pathway in Human Disease
2017 Standout
Idelalisib: First Global Approval
2014
Does the PI3K pathway promote or antagonize regulatory T cell development and function?
2012
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 Standout
Targeting the B-cell receptor signaling pathway in B lymphoid malignancies
2014
Functional Roles of the IgM Fc Receptor in the Immune System
2019 StandoutNobel
Molecular pathogenesis of mantle cell lymphoma
2012
Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway
2021 StandoutNobel
Rethinking Drug Repositioning and Development with Artificial Intelligence, Machine Learning, and Omics
2019
Pathways and mechanisms of venetoclax resistance
2017
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model
2015
Artificial intelligence in drug discovery and development
2020 Standout
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
2012
Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States
2017
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199
2016
Diversity, Mechanisms, and Significance of Macrophage Plasticity
2019 Standout
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
2015
BET Proteins as Targets for Anticancer Treatment
2017
Novel agents for the treatment of chronic lymphocytic leukemia.
2010
Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells
2016
Cytokine Storm
2020 Standout
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct forFLT3-ITD acute myeloid leukemia
2016
The phosphatidylinositol‐3 kinase I inhibitor BKM120 induces cell death in B‐chronic lymphocytic leukemia cells in vitro
2012
Chimeric Antigen Receptor Therapy
2018 Standout
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
Flavonoids as Potential Anti-Inflammatory Molecules: A Review
2022 Standout
Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
2014
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
2016
CAR T cell immunotherapy for human cancer
2018 StandoutScience
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
CSF1R‐ and SHP2‐Inhibitor‐Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor‐Associated Macrophages
2019
P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse
2013
Works of Stephen E. Spurgeon being referenced
Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening
2012
Survival trends in mantle cell lymphoma in the United States over 16 years 1992–2007
2012
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway
2013
The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia
2012
Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.
2009
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
2014
CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
2010
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples
2018
Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma
2015
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
2014
Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic leukemia.
2011
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
2014
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia
2016
Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL.
2013
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
2016
Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
2014
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
2014
Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
2010